Prevalence of use of herbal medicines and complementary and alternative medicine in Europe

Herbal Medicine in Depression: Traditional Medicine to Innovative Drug Delivery

Volumn , Issue , 2016, Pages 135-181

  Hritcu, Lucian ^a   Cioanca, Oana ^b  

^a ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Anxiety; Depression; Europe; Herbal medicines; Pharmacology; Therapy

Indexed keywords

EID: 85012177458     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-14021-6_5     Document Type: Chapter

References (57)

1. Barlow D, Campbell L. Mixed anxiety-depression and its implications for models of mood and anxiety disorders. Comprehens Psychiatry 2000: 41(2 Suppl 1): 55-60.
2. Kessler R, Wittchen H. Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry. 2002,63(Suppl 8): 4-10.
3. Ballenger J, Davidson J, Lecrubier Y, Nutt D, Borkovec T, Rickels K, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001: 62(Suppl 11): 53-8.
4. Menniti-Ippolito F, Gargiulo L, Bologna E, Forcella E, Raschetti R. Use of unconventional medicine in Italy: a nation-wide survey. Eur J Clin Pharmacol. 2002: 58: 61-4.
5. Nissen N, Schunder-Tatzber S, Weidenhammer W, Johannessen H. What attitudes and needs do citizens in Europe have in relation to complementary and alternative medicine? Res Complement Med. 2012: 19(Suppl 2): 9-17.
6. Fischer F, Lewith G, Witt C, Linde K, von Ammon K, Cardini F, et al. High prevalence but limited evidence in complementary and alternative medicine: guidelines for future research. BMC Complement Altern Med. 2014: 14: 46.
7. Fischer HF, Junne F, Witt C, von Ammon K, Cardini F, Fønnebø V, et al. Key issues in clinical and epidemiological research in complementary and alternative medicine -a systematic literature review. Res in Complement Med. 2012: 19(Suppl 2): 51-60.
8. Fischer F, Lewith G, Witt CM, Linde K, Ammon K, Cardini F, et al. A research roadmap for complementary and alternative medicine - what we need to know by 2020. Res Complement Med. 2014: 21: e1-e16.
9. Bodeker G, Ong CK, Grundy C, Burford G, Shein K. WHO Global Atlas of traditional, complementary and alternative medicine: WHO Kobe Centre; 2005.
10. Posadzki P, Alotaibi A, Ernst E. Prevalence of use of complementary and alternative medicine (CAM) by physicians in the UK: a systematic review of surveys. Clin Med. 2012: 12: 505-12.
11. Posadzki P, Watson L, Alotaibi A, Ernst E. Prevalence of complementary and alternative medicine (CAM)-use in UK paediatric patients: a systematic review of surveys. Complement Ther Med. 2013: 21: 224-31.
12. Buono MD, Urciuoli O, Marietta P, Padoani W, De Leo D. Alternative medicine in a sample of 655 community-dwelling elderly. J Psychosom Res. 2001: 50: 147-54.
13. Eardley S, Bishop FL, Prescott P, Cardini F, Brinkhaus B, Santos-Rey K, et al. A systematic literature review of complementary and alternative medicine prevalence in EU. Res Complement Med. 2012: 19(Suppl 2): 18-28.
14. Damase-Michel C, Vié C, Lacroix I, Lapeyre-Mestre M, Montastruc JL. Drug counselling in pregnancy: an opinion survey of French community pharmacists. Pharmacoepidemiol Drug Safety. 2004: 13: 711-5.
15. Bücker B, Groenewold M, Schoefer Y, Schäfer T. The use of complementary alternative medicine (CAM) in 1 001 German adults: results of a populationbased telephone survey. Gesundheitswesen. 2008: 70: e29-e36.
16. Härtel U, Volger E. Inanspruchnahme und Akzeptanz klassischer Naturheilverfahren und alternativer Heilmethoden in Deutschland - Ergebnisse einer repräsentativen Bevölkerungsstudie. Res Complement Med. 2004: 11: 327-34.
17. Lewith GT. Funding for CAM. Br Med J. 2007: 335: 951.
18. Thomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus Survey. J Public Health. 2004: 26: 152-7.
19. Linde K, Berner M, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008: 8: CD000448.
20. Jäger AK, Gauguin B, Andersen J, Adsersen A, Gudiksen L. Screening of plants used in Danish folk medicine to treat depression and anxiety for affinity to the serotonin transporter and inhibition of MAO-A. J Ethnopharmacol. 2013: 145: 822-5.
21. Ernst E. St. John’s Wort, an anti-depressant? A systematic, criteria-based review. Phytomed. 1995: 2: 67-71.
22. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry. 2001: 34: 45-9.
23. Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia. 2007: 27: 1421-3.
24. Jakovljević V, Popović M, Mimica-Dukić N, Sabo A, Gvozdenović L. Pharmacodynamic study of Hypericum perforatum L. Phytomed. 2000: 7: 449-53.
25. Nazıroğlu M, Çiğ B, Özgül C. Modulation of oxidative stress and Ca 2+ mobilization through TRPM2 channels in rat dorsal root ganglion neuron by Hypericum perforatum. Neuroscience. 2014: 263: 27-35.
26. Linde K, Berner M, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008: 8: CD000448.
27. Volz HP. Controlled clinical trials of Hypericum extracts in depressed patients - an overview. Pharmacopsychiatry. 1997, 30: 72-6.
28. Linde K, Berner M, Egger M, Mulrow C. St John’s Wort for depression. 2005.
29. Cervo L, Rozio M, Ekalle-Soppo C, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology. 2002: 164: 423-8.
30. Izzo A. Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004: 42: 139-48.
31. Jung H, Yoo D, Kim W, Nam S, Kim J, Choi J, et al. Valeriana officinalis root extract suppresses physical stress by electric shock and psychological stress by nociceptive stimulation-evoked responses by decreasing the ratio of monoamine neurotransmitters to their metabolites. BMC Complement Alternative Med 2014: 14: 476.
32. Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine. 2008: 15: 2-15.
33. Marder M, Viola H, Wasowski C, Fernández S, Medina JH, Paladini AC. 6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav. 2003: 75: 537-45.
34. Cavadas C, Araujo I, Cotrim MD, Amaral T, Cunha AP. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung. 1995: 45: 753-5.
35. Wasowski C, Marder M, Viola H, Medina JH, Paladini AC. Isolation and Identification of 6-Methylapigenin, a competitive ligand for the brain GABAA receptors, from Valeriana wallichii. Plant Med. 2002: 68: 934-6.
36. Santos MS, Ferreira F, Cunha AP, Carvalho AP, Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Plant Med. 1994: 60: 278-9.
37. Santos MS, Ferreira F, Cunha AP, Carvalho AP, Ribeiro C. Synaptosomal GABA release as influenced by valerian root extract--involvement of the GABA carrier. Arch Int Pharmacodyn Thér. 1994: 327: 220-31.
38. Santos MS, Ferreira F, Faro C, Pires E, Carvalho AP, Cunha AP, et al. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes. Plant Med. 1994: 60: 475-6.
39. Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller C. E. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J Nat Product. 2002: 65: 1479-85.
40. Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav. 2004: 77: 399-404.
41. Wagner H, Jurcic K, Schaette R. Comparative studies on the sedative action of Valeriana extracts, valepotriates and their degradation products Plant Med. 1980: 37: 358-62.
42. European Medicines Agency, Assessment report on Valeriana officinalis L., Radix. 2007: 8.
43. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007: 11: 209-30.
44. Jorm A, Allen N, O’Donnell C, Parslow R, Purcell R, Morgan A. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust. 2006: 185: 368-72.
45. Abdoly M, Farnam A, Fathiazad F, Khaki A, Khaki AA, Ibrahimi A, Afshari F, Rastgar H. Antidepressant-like activities of Ocimum basilicum (sweet Basil) in the forced swimming test of rats exposed to electromagnetic field (EMF). Afr J Pharmacy Pharmacol. 2012: 6: 211-15.
46. Chalchat JC, Özcan MM. Comparative essential oil composition of flowers, leaves and stems of basil (Ocimum basilicum L.) used as herb. Food Chem. 2008: 110: 501-3.
47. Chang X, Alderson PG, Wright CJ. Solar irradiance level alters the growth of basil (Ocimum basilicum L.) and its content of volatile oils. Environ Exp Bot. 2008: 63: 216-23.
48. Gradinariu V, Cioanca O, Gille E, Aprotosoaie AC, Hriţcu L, Hăncianu M. The chemical profile of basil biovarieties and its implication on the biological activity. Farmacia. 2013: 61: 532-639.
49. Gradinariu V, Cioanca O, Hritcu L, Trifan A, Gille E, Hancianu M. Comparative efficacy of Ocimum sanctum L. and Ocimum basilicum L. essential oils against amyloid beta (1-42)-induced anxiety and depression in laboratory rats. Phytochem Rev. 2015: 14: 567-575.
50. Yoo D, Choi J, Kim W, Yoo KY, Lee C, Yoon Y, et al. Effects of Melissa officinalis L. (lemon balm) extract on neurogenesis associated with serum corticosterone and GABA in the mouse dentate gyrus. Neurochem Res. 2011: 36: 250-7.
51. Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytotherapy Res. 2009: 23: 1075-81.
52. Ibarra A, Feuillere N, Roller M, Lesburgere E, Beracochea D. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. Phytomedicine. 2010: 17: 397-403.
53. Noguerón-Merino MC, Jiménez-Ferrer E, Román-Ramos R, Zamilpa A, Tortoriello J, Herrera-Ruiz M. Interactions of a standardized flavonoid fraction from Tilia americana with serotoninergic drugs in elevated plus maze. J Ethnopharmacol. 2015: 164: 319-27.
54. Toker G, Küpeli E, Memisoğlu M, Yesilada E. Flavonoids with antinociceptive and anti-inflammatory activities from the leaves of Tilia argentea (silver linden). J Ethnopharmacol. 2004: 95: 393-7.
55. Liu Z, Xu Z, Zhou H, Cao G, Cong XD, Zhang Y, et al. Simultaneous determination of four bioactive compounds in Verbena officinalis L. by using high-performance liquid chromatography. Pharmacognosy Mag. 2012: 8: 162-5.
56. Lai SW, Yu MS, Yuen WH, Chang RCC. Novel neuroprotective effects of the aqueous extracts from Verbena officinalis Linn. Neuropharmacol. 2006: 50: 641-50.
57. Jawaid T, Imam SA, Kamal M. Antidepressant activity of methanolic extract of Verbena officinalis Linn. plant in mice. Asian J Pharm Clin Res. 2015: 8: 308-10.